Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
CHU de Quebec-Universite Laval
80 participants
Jan 5, 2026
INTERVENTIONAL
Conditions
Summary
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.
Eligibility
Inclusion Criteria5
- Multiple myeloma patient:
- ≥ 18 years old
- ≥ 1 prior lines of therapy
- Receiving a BCMA-directed T-cell Engager therapy (starting on treatment)
- On previous Ig support or not
Exclusion Criteria2
- Less than 18 years old
- Pregancy or breastfeeding
Interventions
Target trough IgG level of 8-10 g/L
Target trough IgG level of 4-6 g/L
If, during follow-up, the patient presents recurrent or severe infections and/or total IgG level less 4 g/L, crossover to group A or B
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07094048